title: Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma.
abstract: We report the activity and toxicity of docetaxel in 12 evaluable heavily pretreated patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. In all, 42% achieved a partial response, 25% achieved stable disease. Median duration of response was 16 (10-21) weeks. The median overall survival was 70 (9-178) weeks and for responders it was 120 (22-178) weeks. One patient developed one episode of neutropenic sepsis. Docetaxel has limited activity in this group of patients.
authors.affiliation: Cancer Research Centre, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK. jmzekri@hotmail.com
authors.forename: J M
authors.initials: JM
authors.lastname: Zekri
authors.forename: R E
authors.initials: RE
authors.lastname: Hough
authors.forename: J M
authors.initials: JM
authors.lastname: Davies
authors.forename: R
authors.initials: R
authors.lastname: Molife
authors.forename: B W
authors.initials: BW
authors.lastname: Hancock
authors.forename: P C
authors.initials: PC
authors.lastname: Lorigan
mesh_terms: D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D001772:Blood Cell Count; D018572:Disease-Free Survival; D000077143:Docetaxel; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011379:Prognosis; D015996:Survival Rate; D043823:Taxoids; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel